Raymond Poon

Mr. Raymond Poon

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in British Journal of Radiology
Verified
Journal Article
Closed access
AMAamer Mahmud
Aamer Mahmud
RPRaymond Poon
Raymond Poon
DJDerek Jonker
Derek Jonker
Objective:The aim of this study was to systematically review the literature to synthesize and summarize the evidence surrounding the clinical utility of positron emission tomography (PET) imaging in patients with anal canal cancer.Methods:The literature was searched using MEDLINE, EMBASE and Cochrane Database of Systematic Reviews databases. Studies comparing PET or PET/CT with conventional imaging in the staging, response evaluation and follow-up of anal canal cancer were deemed eligible for inclusion.Results:17 studies met the inclusion criteria. For the detection of primary tumour in situ, the pooled sensitivity was 99% for PET or PET/CT and 67% for CT. For the detection of inguinal lymph nodes, PET/CT had an overall sensitivity of 93% and specificity of 76%. PET or PET/CT upstaged 5.1 to 37.5% of patients and downstaged 8.2 to 26.7% of patients. Treatment plans were modified in 12.5 to 59.3% of patients, which consisted mainly of radiotherapy dose or field changes. Complete response on PET or PET/CT i...

28 March 2017 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
ASAmit Singnurkar
Amit Singnurkar
RPRaymond Poon
Raymond Poon
UMUr Metser
Ur Metser

11 December 2022 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
ASAmit Singnurkar
Amit Singnurkar
RPRaymond Poon
Raymond Poon
JDJay Detsky
Jay Detsky

6 October 2015 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Verified
Journal Article
Open access
PDF file
JBJorge G. Burneo
Jorge G. Burneo
RPRaymond Poon
Raymond Poon
SKSarah Kellett
Sarah Kellett
OSO. Carter Snead
O. Carter Snead
The role of fludeoxyglucose F 18 positron emission tomography (PET) in the presurgical evaluation of patients with medically intractable epilepsy continues to be refined. The purpose of this study was to systematically review the literature to assess the diagnostic accuracy and utility of PET in this setting. Thirty-nine studies were identified through MEDLINE and EMBASE databases that met the inclusion criteria. In adult patients, PET hypometabolism showed a 56 to 90% agreement with seizure onset localized by intracranial electroencephalogram (pediatric: 21 to 86%). In temporal lobe epilepsy patients with good surgical outcome, PET displayed moderate to high sensitivity in localizing the seizure focus (range: 71 to 89%). The sensitivity increased by 8 to 23% when PET results were combined with magnetic resonance imaging or electroencephalogram. PET has been shown to affect patient management by improving the guidance of intracranial electrodes placement, altering the decision to perform surgery, or excluding patients from further evaluation.

20 April 2021 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
HHHal Hirte
Hal Hirte
RPRaymond Poon
Raymond Poon
XYXiaomei Yao
Xiaomei Yao
TMTaymaa May
Taymaa May
JEJosee-Lyne Ethier
Josee-Lyne Ethier
LELaurie M. Elit
Laurie M. Elit

8 January 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
HHHal Hirte
Hal Hirte
RPRaymond Poon
Raymond Poon
XYXiaomei Yao
Xiaomei Yao
TMTaymaa May
Taymaa May
JEJosee-Lyne Ethier
Josee-Lyne Ethier
LELaurie M. Elit
Laurie M. Elit
Background: This study aims to provide guidance for the use of neoadjuvant and adjuvant systemic therapy in women with newly diagnosed stage II–IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma. Methods: EMBASE, MEDLINE, and Cochrane Library were investigated for relevant systematic reviews and phase III trials. Articles focusing on consolidation and maintenance therapies were excluded. Results: For women with potentially resectable disease, primary cytoreductive surgery, followed by six to eight cycles of intravenous three-weekly paclitaxel and carboplatin is recommended. For those with a high-risk profile for primary cytoreductive surgery, neoadjuvant chemotherapy can be an option. Adjuvant chemotherapy with six cycles of dose-dense weekly paclitaxel plus three-weekly carboplatin can be considered for women of Japanese descent. In women with stage III or IV disease, the incorporation of bevacizumab concurrent with paclitaxel and carboplatin is not recommended for use as adjuvant therapy unless bevacizumab is continued as maintenance therapy. Intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel can be considered for stage III optimally debulked women who did not receive neoadjuvant chemotherapy. However, intraperitoneal administration of chemotherapy with bevacizumab should not be considered as an option for stage II–IV optimally debulked women. Discussion: The recommendations represent a current standard of care that is feasible to implement and valued by both clinicians and patients.